

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA 复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ANNOUNCEMENT PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ITS APPENDICES

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company hereby announces that, as considered and approved at the Board meeting and the meeting of the board of supervisors of the Company held on 14 May 2024, respectively, it is proposed to make certain amendments (the “**Proposed Amendments**”) to the Articles of Association of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (《上海復星醫藥（集團）股份有限公司章程》) (the “**Articles of Association**”) and its appendices, namely the Rules of Procedure for the General Meeting of Shareholders (《股東大會議事規則》), the Rules of Procedure for the Board of Directors (《董事會議事規則》) and the Rules of Procedure for the Board of Supervisors (《監事會議事規則》), and recommend the same to the shareholders of the Company (the “**Shareholders**”) for consideration and, if thought fit, approval.

The Proposed Amendments are proposed in light of, among other things, the abolition of the Special Regulations of the State Council on the Overseas Offering and Listing of Shares by Joint Stock Limited Companies (《國務院關於股份有限公司境外募集股份及上市的特別規定》) and the Mandatory Provisions for Companies Listing Overseas (《到境外上市公司章程必備條款》) on 31 March 2023, the formulation and issuance of the Measures for the Administration of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》) and the amendment of the Regulatory Guidelines for Listed Companies No. 3 — Cash Dividends of Listed Companies (《上市公司監管指引第3號—上市公司現金分紅》) (effective from 15 December 2023) and the Guidelines for the Articles of Association of Listed Companies (《上市公司章程指引》) (effective from 15 December 2023) by the China Securities Regulatory Commission, and certain recent amendments to the Listing Rules, as well as taking into account the actual conditions of the Company.

CIRCULAR

The above Proposed Amendments are subject to approval by the Shareholders by way of special resolutions at a general meeting of the Company and the respective class meetings of the holders of the Company's domestic shares and overseas listed foreign shares.

A circular containing, among others, details of the Proposed Amendments, together with notices convening an annual general meeting and the relevant class meetings will be despatched to the Shareholders in due course.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
14 May 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*